Vir Biotechnology Inc
NASDAQ:VIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vir Biotechnology Inc
NASDAQ:VIR
|
US |
|
P
|
Payton Industries Ltd
TASE:PAYT
|
IL |
|
Ping An Insurance Group Co of China Ltd
SSE:601318
|
CN |
|
B
|
Bajaj Steel Industries Ltd
BSE:507944
|
IN |
|
B
|
Bank of Ireland Group PLC
SWB:BIRG
|
IE |
|
Lotte Chemical Corp
KRX:011170
|
KR |
|
A
|
AURELIUS Equity Opportunities SE & Co KgaA
XETRA:AR4
|
DE |
|
G
|
Guangdong Green Precision Components Co Ltd
SZSE:300968
|
CN |
|
E
|
Etga Group Ltd
TASE:ETGA
|
IL |
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
HK |
|
B
|
Beken Corp
SSE:603068
|
CN |
|
Virinchi Ltd
BSE:532372
|
IN |
|
W
|
Wilmar Cahaya Indonesia Tbk PT
IDX:CEKA
|
ID |
Vir Biotechnology Inc
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.
Strategic Partnership: Vir announced a major global collaboration with Astellas to co-develop and co-commercialize VIR-5500 for prostate cancer, with up to $1.7 billion in upfront and milestone payments.
Positive Phase I Data: VIR-5500 Phase I results showed strong safety and efficacy, with deep and durable PSA responses, and minimal high-grade cytokine release syndrome, even in heavily pretreated patients.
Reduced Costs: Vir reported a 10% reduction in R&D expenses and a 23% reduction in SG&A for 2025 compared to 2024, reflecting ongoing cost discipline.
Financial Strength: Vir ended 2025 with approximately $782 million in cash and expects its cash runway to extend into the second quarter of 2028.
Pipeline Expansion: The Astellas deal enables Vir to accelerate other programs in its PRO-XTEN platform, with 7 preclinical T cell engagers advancing toward candidate selection.
